Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Timing for rebalancing crypto portfolios depends on volatility, drift from targets, and your risk tolerance, with clear trigger rules.
19,022 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Two retirees withdraw the same amount from $2M portfolios, but after federal and state taxes they diverge sharply. Th...
As oil markets shift, offshore drilling and onshore completion services offer different paths to profits. This compar...
Investors in YMAX face layered fees from a fund-of-funds structure. With a 1.33% expense ratio on top of underlying E...
With American Express set to report on July 24, analysts say a durable franchise, disciplined capital returns, and a ...
Three ETFs are positioning investors for the next leg of AI-driven growth, offering diversified exposure as markets r...
A new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Carnival's June earnings set the tone for a post-pandemic rebound in the cruise industry. This analysis compares the ...
Institutional landlords are stepping up the sale of single-family rentals as the ROAD Act takes effect. Early data sh...
Virtus InfraCap’s new VPFF ETF started trading in July 2026, offering 0.80% expenses and an actively managed approach...
Imagine turning a modest $100 monthly investment into a meaningful future. This guide breaks down how a stock that co...
A notable fund adds Masimo stock, signaling confidence in noninvasive monitoring tech. This analysis breaks down the ...